Improvement in the neutron beam collimation for application in boron neutron capture therapy of the head and neck region

1. Kato, I. et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl. Radiat. Isot. 61, 1069–1073 (2004).

2. Aihara, T. et al. Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck. Int. J. Clin. Oncol. 19,

437–444 (2014).

3. Kankaanranta, L. et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis

of a phase I/II trial. Int. J. Radiat. Oncol. 82, e67–e75 (2012).

4. Haapaniemi, A. et al. Boron neutron capture therapy in the treatment of recurrent laryngeal cancer. Int. J. Radiat. Oncol. 95,

404–410 (2016).

5. Tanaka, H. et al. Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron

capture therapy. Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms 267, 1970–1977 (2009).

6. Tanaka, H. et al. Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS). Appl.

Radiat. Isot. 69, 1642–1645 (2011).

7. Hirose, K. et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent

or locally advanced head and neck cancer (JHN002): an open-label phase II trial. Radiother. Oncol. 155, 182–187 (2021).

Scientific Reports |

(2022) 12:13778 |

https://doi.org/10.1038/s41598-022-17974-7

11

Vol.:(0123456789)

www.nature.com/scientificreports/

A Self-archived copy in

Kyoto University Research Information Repository

https://repository.kulib.kyoto-u.ac.jp

8. Sato, T. et al. Features of particle and heavy ion transport code system (PHITS) version 3.02. J. Nucl. Sci. Technol. 55, 684–690

(2018).

9. Sakurai, Y. & Kobayashi, T. Characteristics of the KUR Heavy Water Neutron Irradiation Facility as a neutron irradiation field with

variable energy spectra. Nucl. Instrum. Methods Phys. Res. Sect. A Accel. Spectrometers Detect. Assoc. Equip. 453, 569–596 (2000).

10. Hu, N. et al. Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against

an independent Monte Carlo dose calculation system. Radiat. Oncol. 16, 1–13 (2021).

11. Coderre, J. A. et al. Derivations of relative biological effectiveness for the high-let radiations produced during boron neutron

capture irradiations of the 9l rat gliosarcoma in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 27, 1121–1129 (1993).

12. Coderre, J. A. et al. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. Radiat. Res. 149, 163–170 (1998).

13. Fukuda, H. et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the

normal skin and tumor. Australas. Phys. Eng. Sci. Med. 26, 97–103 (2003).

14. Coderre, J. A., Morris, G. M., Micca, P. L., Fisher, C. D. & Ross, G. A. Comparative assessment of single-dose and fractionated

boron neutron capture therapy. Radiat. Res. 144, 310–317 (1995).

15. Kumada, H. et al. Verification of the computational dosimetry system in JAERI (JCDS) for boron neutron capture therapy. Phys.

Med. Biol. 49, 3353–3365 (2004).

16. Kumada, H. et al. Verification for dose estimation performance of a Monte-Carlo based treatment planning system in University

of Tsukuba. Appl. Radiat. Isot. 166, 109222 (2020).

17. González, S. J. & Santa Cruz, G. A. The photon-isoeffective dose in Boron neutron capture therapy. Radiat. Res. 178, 609–621

(2012).

Author contributions

N.H. designed the research, conducted the simulations, analysed the data, and wrote the paper; H.T. and K.O.

supervised the research and gave feedback; R.K. assisted with the data collection and analysis, K.A., S.Y., and

M.M. helped with the experimental set up; K.N. and A.T. offered clinical feedback; all authors contributed to

the manuscript. Written informed consent was obtained from legal guardian/parents for minors in manuscript.

Competing interests The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to N.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or

format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the

Creative Commons licence, and indicate if changes were made. The images or other third party material in this

article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the

material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from

the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/.

© The Author(s) 2022

Scientific Reports |

Vol:.(1234567890)

(2022) 12:13778 |

https://doi.org/10.1038/s41598-022-17974-7

12

...